Fig. 1
From: Molecular genomic and epigenomic characteristics related to aspirin and clopidogrel resistance
Mediators and genes of arachidonic acid metabolism and clopidogrel activation targeted in the present study [4, 10]. 6-keto PGF1α, 6-keto prostaglandin F1α; ADP, adenosine diphosphate; ALOX5, 5-lipoxygenase gene; ALOX12, 12-lipoxygenase gene; ALOX15, 15-lipoxygenase gene; ARU, aspirin reaction units; COX1, cyclooxygenase 1 gene; COX2, cyclooxygenase 2 gene; CYP2C19, cytochrome P450 2C19 gene; LTB4, leukotriene B4; LXA4, lipoxin A4; P2Y12, a chemoreceptor for adenosine diphosphate; PGE2, prostagladin E2; PGE2S, prostaglandin E2 synthase gene; PGE2R, prostaglandin E2 receptor gene; PGIS, prostaglandin I synthase gene; PGIR, prostaglandin I receptor gene; PRU, P2Y12 reaction units; TXAS1, thromboxane A synthase 1 gene; TXA2R, thromboxane A2 receptor gene; TXB2, thromboxane B2